$122.21
1.61% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Todd Tushla - Vice President of Investor Relations Conference Call Participants Chris Shibutani - Goldman Sachs Paul ...
Neutral
PRNewsWire
4 days ago
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO , Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter...
Positive
Seeking Alpha
24 days ago
Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. Neurocrine's NBI-1117568 demonstrated encouraging Phase 2 schizophrenia data, though dose inconsistencies raised questions about efficacy. The stock's recent decline is an overreaction, presenting a buying opportunity given its CNS pipeline and Ingrezza'...
Neutral
PRNewsWire
25 days ago
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
Neutral
PRNewsWire
about one month ago
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders® SAN DIEGO , Sept. 30, 2024 /PRNewswire/ -- Neurocrine Bioscienc...
Neutral
Investors Business Daily
about one month ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
PRNewsWire
about one month ago
SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m.
Negative
Reuters
about 2 months ago
Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today